PRODUCT INFORMATION

Muvalaplin

Item No. 39746



CAS Registry No.:	2565656-70-2
Formal Name:	(αS,α′S,α′′S,3R,3′R,3′′R)-α,α′,α′′-[nitrilotris(methylene-3,1-phenylenemethylene)] *tris*-3-pyrrolidineacetic acid
Synonym:	LY3473329
MF:	$C_{42}H_{54}N_4O_6$
FW:	710.9
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Muvalaplin is supplied as a solid. Aqueous solutions of muvalaplin can be prepared by directly dissolving the solid in aqueous buffers. Muvalaplinis is slightly soluble (0.1-1 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

Muvalaplin is a trivalent binder of apolipoprotein A (ApoA).[1] It selectively binds to ApoA kringle domain IV type 8 (KIV8) over KIV2 (IC_{50}s = 22 and 3,900 nM, respectively). Muvalaplin also binds to rat plasminogen (K_d = <10 nM). It reduces the formation of lipoprotein A in a cell-free assay (IC_{50} = 0.09 nM). Muvalaplin decreases plasma levels of lipoprotein A in mice expressing both human ApoA and human ApoB (*LPA* x *ApoB100*; ED_{50} = 3 mg/kg). It reduces plasma levels of lipoprotein A in cynomolgus monkeys when administered at a dose of 100 mg/kg per day. Muvalaplin (31.6 mg/kg for four days) decreases *ex vivo* plasmin activity and plasminogen levels after administration in rats.

Reference

1. Diaz, N., Perez, C., Escribano, A.M., *et al.* Discovery of potent small-molecule inhibitors of lipoprotein(a) formation. *Nature* **629(8013)**, 945-950 (2024).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM